Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic Alterations in PIK3CA -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors

8 Mar 2021

Abstract excerpt

Abstract PI3Kα inhibitors have shown clinical activity in PIK3CA-mutated estrogen receptor-positive (ER+) patients with breast cancer. Using whole genome CRISPR/Cas9 sgRNA knockout screens, we identified and validated several negative regulators of mTORC1 whose loss confers resistance to PI3Kα inhibition. Among the top candidates were TSC1, TSC2, TBC1D7, AKT1S1, STK11, MARK2, PDE7A, DEPDC5, NPRL2, NPRL3,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to CRISPR and Genetic Engineering
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33685991
DOI: 10.1158/0008-5472.can-20-3232

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic Alterations in PIK3CA -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα InhibitorsPMID 33685991Read ↗

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted TherapeuticsSemantic proximity Read ↗

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.Semantic proximity Read ↗

The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future DirectionsSemantic proximity Read ↗

PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.Semantic proximity Read ↗

Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.Semantic proximity Read ↗

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical ChallengesSemantic proximity Read ↗

Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.Semantic proximity Read ↗

Targeting PI3K inhibitor resistance in breast cancer with metabolic drugsSemantic proximity Read ↗

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-NegativeSemantic proximity Read ↗

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.Semantic proximity Read ↗

Insulin receptor substrate 2 (IRS2) confers resistance to PI3K pathway inhibition in <i>PIK3CA</i> mutant breast cancerSemantic proximity Read ↗

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.